CD19 and acute lymphoblastic leukemia: Furthermore, lineage switch seems to occur more commonly in children with ALL treated with chimeric antigen receptor T (CAR-T) cells or antibody therapy (such as blinatumomab) targeting the principal lineage marker of B-cell lymphoblasts, CD19.